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The presence of recurrent high-risk mutations in cyclin-dependent kinase inhibitor 2A/cyclin-dependent kinase
4 (CDKN2A/CDK4) among melanoma-prone families suggests that a high-throughput, multiplex assay could
serve as an effective initial screening tool. To this end, we have developed a multiplex bead-based assay for
high-throughput CDKN2A/CDK4 genotyping in the context of familial melanoma. Genomic DNA from 1,603
subjects (1,005 in training set and 598 in validation set) were amplified by multiplex PCR using five CDKN2A/
CDK4 primer sets followed by multiplex allele-specific primer extension for 39 distinct germline variants. The
products were then sorted and analyzed using the Luminex xMAP system. Genotypes were compared with
previously determined sequence data. In the Toronto training cohort, all 145 samples with known variants were
detected by the bead assay (100% concordance). Analysis of the 598 samples from the GenoMEL validation set
led to identification of 150/155 expected variants (96.77%). Overall, the bead assay correctly genotyped 1,540/
1,603 (96.07%) of all individuals in the study and 1,540/1,545 (99.68%) of individuals whose variants were
represented in the probe set. Out of a total of 62,517 allelic calls, 62,512 (99.99%) were correctly assigned. The
multiplex bead-based assay is an accurate method for genotyping CDKN2A/CDK4 variants and is potentially
useful in genotyping low-to-moderate melanoma risk single-nucleotide polymorphisms.
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INTRODUCTION
Cutaneous malignant melanoma (CMM) accounts for B2%
of new cancer cases diagnosed annually in North America.
Of these cases, 5–10% of individuals with CMM have an
affected family member, indicative of some degree of
inherited predisposition. The primary locus involved in
familial CMM to date is cyclin-dependent kinase inhibitor
2A (CDKN2A), which encodes the cell cycle regulator
protein p16, and when mutated accounts for 25–40% of
familial CMM cases (Zuo et al., 1996; Goldstein et al., 2006,
2007). The p16 protein is encoded by exons 1a, 2, and 3. An
alternative transcript, comprising exons 1b, 2, and 3, encodes
a protein, designated as p14ARF, because the exon 2
sequence is translated in an alternative reading frame (ARF)
relative to that of p16. Germline mutations in exon 1b of
p14ARF have been detected in melanoma-prone families
(Rizos et al., 2001a, b; Hewitt et al., 2002; Harland et al.,
2005). In addition, rare mutations in the gene encoding
cyclin-dependent kinase 4 (CDK4)—the primary enzyme
inhibited by p16 binding—have been identified in a small
number of CMM kindreds worldwide (Zuo et al., 1996; Soufir
et al., 1998; Molven et al., 2005; Goldstein et al., 2006).
The identification of these genes and their association
with familial CMM has highlighted a need for flexible, cost-
effective, high-throughput genotyping methods, which can
eventually be transferred to a diagnostic setting when
melanoma risk profiling becomes clinically practical. In this
ORIGINAL ARTICLE
480 Journal of Investigative Dermatology (2011), Volume 131 & 2011 The Society for Investigative Dermatology
Received 4 May 2010; revised 2 August 2010; accepted 22 August 2010;
published online 18 November 2010
1Departments of Medicine and Medical Biophysics, University of Toronto,
Toronto, Ontario, Canada; 2Wellman Center for Photomedicine, Department
of Dermatology and MGH Cancer Center, Massachusetts General Hospital,
Boston, Massachusetts, USA; 3Section of Epidemiology and Biostatistics,
Leeds Institute of Molecular Medicine, University of Leeds, St James’s
Hospital, Leeds, UK; 4Oncogenomics Laboratory, Queensland Institute of
Medical Research, Brisbane, Queensland, Australia; 5Genetic Epidemiology
Branch, National Cancer Institute, Bethesda, Maryland, USA; 6Melanoma
Unit, Dermatology Department, Hospital Clinic, IDIBAPS and CIBER de
Enfermedades Raras, Barcelona, Spain; 7Department of Dermatology, Leiden
University Medical Center, Leiden, The Netherlands; 8Department of
Oncology, Biology and Genetics, University of Genoa, Genoa, Italy and
9Laboratory of Genetics of Rare Hereditary Cancers, San Martino Hospital,
Genoa, Italy
Correspondence: Hensin Tsao, Department of Dermatology and Wellman
Center for Photomedicine, Massachusetts General Hospital, 55 Fruit Street,
Boston, Massachusetts 02114, USA. E-mail: htsao@partners.org
Abbreviations: ARF, alternative reading frame; ASPE, allele-specific primer
extension; CDK4, cyclin-dependent kinase 4; CDKN2A, cyclin-dependent
kinase inhibitor 2A; CMM, cutaneous malignant melanoma; SNPs, single-
nucleotide polymorphisms
report, we describe the development and validation of a, to
our knowledge, previously unreported, multiplex bead-based
assay to detect CMM-associated variants. This assay employs
the xTAG (formerly Tag-It) Microsphere-Based Universal
Array Genotyping platform (Luminex Molecular Diagnostics
(formerly TM Bioscience Corporation), Toronto, Canada)
originally described by Bortolin et al. (2004) in relation to
thrombophilia.
The CMM-specific mutation detection assay described
here can be readily modified to reflect certain population-
specific mutations and to include, to our knowledge,
previously unreported, mutations or low- to moderate-risk
alleles that may be shown to be associated with CMM. This
study demonstrates the use of a microsphere-based array
assay for the detection of 32 common CDKN2A variants, two
CDK4 mutations, and five p14ARF variants among a large
collection of familial melanoma samples from around the
world.
RESULTS
Primary development of the multiplex bead-based assay
was carried out on 1,005 banked DNA samples from
CMM-affected individuals, unaffected relatives, and spouses
referred to the Familial Melanoma Clinic at the Toronto-
Sunnybrook Regional Cancer Centre (Toronto, Canada), for
which the DNA material was successfully amplified (Table 1).
As the 1-8dup8 mutation (N¼ 13) is a perfect repeat and
undetectable by the allele-specific primer extension (ASPE)-
based strategy, this variant was not incorporated into the
bead assay. Thus, for the initial Toronto screen, 1,005
samples (that is, 1018-13) were blindly subjected to analysis
for 39 variants (32 CDKN2A variants in one assay, 2 CDK4,
and 5 p14ARF splice-site variants in another; Supplementary
Table S1 and S2 online). In total, 145/1,005 (14.42%)
samples were shown to harbor an identifiable CDKN2A
variant, of which 65 (6.46%) samples carried the p.A148T
polymorphism. Figure 1 depicts an example of a hetero-
zygous p.T93P CDKN2A mutation with wild-type sequence
at all other variant sites. There was 100% concordance
between the bead-based assay and DNA sequencing; we in
fact detected a CDK4 p.R24C mutation that was previously
undetected and subsequently confirmed by DNA sequencing.
None of the 1,005 Toronto samples screened harbored a
p14ARF variant and none were detected in the bead assay.
Our validation phase was then expanded to include 628
samples from CMM melanoma pedigrees supplied by the
international melanoma genetics consortium, GenoMEL. The
bead assay was performed blindly on each sample. A total
of 30/628 (4.77%) DNA specimens failed to amplify. From
the 598 scorable samples, 150/598 (25.08%) were found
Table 1. Summary of samples assayed in study
Total
Failed
reaction
Samples
scored
Total samples
with variants
1-8dup8
mutations
(not in assay)
Unprobed
variants
Probed
variants
Correct
variants
scored
Missed
variants
Total
SNPs
interrogated
SNPs
assigned
correctly
Toronto 1,027 22 1,005 158 13 0 145 145 0 39,195 39,195
Barcelona 46 9 37 25 2 71 16 16 0 1,443 1,443
NCI-US 62 1 61 43 3 42 36 33 33 2,379 2,376
NCI-Italy 12 1 11 5 0 24 3 3 0 429 429
Genoa 14 2 12 13 0 25 11 11 0 468 468
Leiden 25 1 24 10 0 26 8 8 0 936 936
Queensland 150 10 140 35 3 87 24 24 0 5,460 5,460
Leeds 226 6 220 57 7 0 50 50 0 8,580 8,580
Boston 93 0 93 12 2 38 7 5 29 3,627 3,625
Validation 628 30 598 200 17 28 155 150 5 23,322 23,317
0.9677 0.9997
Total 1,655 52 1,603 358 30 28 300 295 5 62,517 62,512
0.9833 0.9999
Abbreviations: NCI, National Cancer Institute; SNP, single-nucleotide polymorphism.
Affected variants:
1p.D84Y, p.L65P, p.R87W (4), p.V59G. Parentheses designate frequency of variants.
2p.N71S (2), p.R58X (2).
3c.241_254del14 (2), c.IVS2+1G4T.
4p.L65P (2).
5p.R58X (2).
6p.G23R (2).
7p.L16P (2), p.L32P (2), p.Q50R (2), p.V51F (2).
8p.W15X (2), p.A60T.
9p.A148T(2).
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to harbor a variant using the bead-based assay. When the
sequence results were unblinded, 200/598 (33.44%)
samples actually carried a variant. There were 45 mutations
that could not have been detected based on assay design
(seventeen 1-8dup8 mutations and 28 unprobed mutations;
Table 1). For the 155 variants that were ‘‘eligible’’ for the
assay, 150 were properly identified (150/155; 96.77%). There
were also no samples in the validation set with a p14ARF
variant.
When the data from the training and validation sets were
combined, 295/300 (98.33%) eligible mutations were suc-
cessfully detected. However, as personal genotyping includes
the accurate assignment of wild-type states, on an individual
level, 1,540/1,603 (96.07%) of all available patient samples
were correctly genotyped (that is, variant(s) carrier versus
wild type). This somewhat overestimates the error rate, as
58 individuals had mutations not represented in the probe
set. If these individuals were censored, the assay correctly
genotyped 1,540/1,545 (99.68%) of the individuals with
genotypes eligible for the assay.
Unlike sequencing, the bead assay performs 39 distinct
allelic interrogations from 39 separate probe sets. Thus, it is
also reasonable to measure the performance of the assay
based on percentage of correct variant assignments. For
ineligible cases, in which the mutations were not represented
by one of the 39 probes, the assay was agnostic to the actual
mutation, but still made 39 correct sequence assignments at
the individual variants. When considering sequence assign-
ments in this study, a total of 62,517 alleles were analyzed
with only 5 incorrect calls. The bead-based assay is therefore
99.98% accurate at allele scoring.
Four variants that had probe representation but were
missed by the bead assay (false negatives) included two
c.241_254del14 mutations, one splice-site variant (sp3:
c.IVS2þ1G4T), and two p.A148T polymorphisms. One
sample returned a false-positive result by being erroneously
called as a p.G23D mutation when in actual fact the sample
carried a mutation not included in the single-nucleotide
polymorphism (SNP) panel. This false-positive result cannot
be explained, as when we repeated the assay it appeared as
wild type. This was likely due to PCR product quality and/or
quantity variations between the original and repeat runs.
There were 28 variants among GenoMEL samples that were
not included in the original assay (Table 1).
DISCUSSION
A robust ‘‘lab-on-a-chip’’ is an appealing notion in the
emerging era of point-of-care diagnostics. Inherent to the
fabrication of a genetic lab-on-a-chip is the need for a flexible
platform that can respond to an enlarging repertoire of risk
loci and the specific panel of founder changes embedded
within certain populations. In this manuscript, we developed
a, to our knowledge, previously unreported, multiplex bead-
based assay, which can accurately genotype variants at the
two established high-risk melanoma loci (that is, CDKN2A
and CDK4), and validated this assay on a cohort of familial
melanoma patients. The fundamental rationale for develop-
ing such a system comes from the collective GenoMEL
experience. A significant fraction of the 190 CDKN2A and
CDK4 mutation-bearing families reported by the consortium
harbor recurrent germline mutations (Goldstein et al., 2006);
in fact, the 27 most prevalent variants account for 480% of
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Figure 1. Example of a heterozygous p.T93P mutation in an individual. The allelic ratio is B0.5, as expected in a heterozygous state. SA-PE, streptavidin-
conjugated phycoerythrin.
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the detected mutations among the melanoma families
ascertained by GenoMEL. The high frequency of founder
changes observed among this cohort makes this an ideal
collection to develop this, to our knowledge, previously
unreported, mutation-interrogation platform. However, the
assay was developed with a single set of testable variants in
mind and is not expected to capture all possible CDKN2A
mutations latent in the CMM population; thus, our assay
should be viewed only as a first-generation design that can
be readily expanded to include additional melanoma risk
alleles.
A total of 1,603 patient DNA samples were genotyped by
both the Tag-It assay and DNA sequencing for exons 1a, 2,
and 3 of the CDKN2A gene, exon 2 of the CDK4 gene, and
exon1b of p14ARF. With only five missed calls, the results
between the bead-based assay and DNA sequencing were
98.33% in agreement by genotyping and 99.99% accurate
by SNP calls.
In terms of economics, the cost for commercial p16
testing (that is, Melaris, Myriad Genetics, Salt Lake City, UT)
without p14ARF or CDK4 analysis is $900 (price sheet as of 1
April 2010). At the research level, direct sequencing (forward
and reverse) of the five exons (four CDKN2A and one CDK4;
10 separate reactions) costs approximately $20 per sample at
the Massachusetts General Hospital sequencing core ($2 per
sequence reaction). The single sample cost for the bead
analysis is approximately $9.35 (25 for 70 primer sets þ 13
per bead color70 bead colors). With further refinement,
the economic advantage of bead assays could be further
enhanced. Operationally, one long-term goal of the bead
assay is for allelic discrimination at many discrete loci.
In this initial proof-of-concept, the 39 variants can be found
in five exons; however, if the 39 variants were in fact
embedded in 39 separate exons, the cost of direct sequencing
would be much higher. Although still early in terms of
technical development, these results are encouraging
for this, to our knowledge, previously unreported, bead-
based assay.
In terms of assay development, the main technical
advantages of this platform are its ‘‘plexibility’’ and flexibility.
Both fluorescent-based and matrix-assisted laser desorption/
ionization-driven SNP detection offer significantly lower
multiplexing capabilities despite the flexibility of their design.
With newer systems, the bead-based assay can easily
accommodate up to 500 SNPs in a single tube; thus, nearly
all known variants of CDKN2A, CDK4, and ARF can be
incorporated into a single assay along with a host of low- to
moderate-risk CMM alleles. Solid array systems (that is,
microarray ‘‘chips’’) present extraordinary capabilities in
terms of parallel SNP analysis (41 106 SNPs); however,
there is little, if any, user input into the choice of SNPs or
assay design unless a ‘‘custom chip’’ is manufactured. Unlike
solid-phase microarrays, however, liquid bead arrays offer
several unique advantages: the spherical substrate allows for
a greater analytical surface area, the liquid phase mobility
encourages more efficient mixing of cognate molecules, and
the encoded beads can be more readily manipulated.
Emerging technologies that capitalize on microfluidics also
hold promise for heightened throughput and flexibility
(Derveaux et al., 2008).
A major potential application of the bead-array assay is in
SNP-based risk profiling. Over the past few years, a harvest
of CMM disease-associated SNPs has been uncovered
through large and robust genome-wide association studies
(Udayakumar and Tsao, 2009). From a scientific perspective,
follow-up analysis of putative regions will need to be
performed with greater SNP densities. As such, assays need
to be rapidly developed for high-throughput analysis without
sacrificing multiplexing capabilities. The bead assay is an
ideal research platform for saturating these regions with
additional SNP markers in hopes of refining the disease-
associated intervals. As, to our knowledge, previously
unreported, melanoma risk alleles are discovered, the single
tube assay, which measures a single allele in a single
reaction, will have to be replaced by array-based methods
to be capable of analyzing multiple alleles in a single
reaction. Thus, the bead assay can be configured to be a truly
‘‘personalized’’ risk predictor, allowing SNP panel selection
based on historical or phenotypic features. Although the ideal
target audience for this bead assay has not been established,
as disease-specific risk predictors (including melanoma)
become more readily available in the commercial setting,
physicians will be able to integrate genotype results across
multiple loci with patient exposure information in order to
better estimate the risk.
Bead-based analytics have already been deployed in the
clinical setting (Bortolin et al., 2004). Bortolin et al. devel-
oped the xTAG (formerly Tag-It) platform for the multiplex
analysis of a panel of thrombophilia-associated SNPs. They
reported 100% concordance between the xTAG assay and
direct DNA sequencing data for 736 SNP determinations
from genomic DNA from 132 patients. They also used the
Luminex xMAP system and concluded that the xTAG
platform is a highly accurate, multiplexed, high-throughput
SNP-detection assay. Although currently premature, an
extended panel of high-, moderate-, and low-risk alleles
could eventually be developed into a useful melanoma risk
profiling tool.
There are several limitations to our analysis. Similar to
other allele-specific platforms, variants are interrogated by
the bead array rather than discovered. Rare missense
mutations, in-frame insertions, large deletions, and mutations
not included in the assay (Orlow et al., 2007) cannot be
successfully recovered. For example, the common 1-8dup8
mutation, in which the first eight amino acids of exon 1a are
exactly duplicated, could not be incorporated into the assay,
as wild-type and mutant sequences cannot be distinguished
from each other by oligonucleotide differences. For muta-
tional screening, several studies, including those from
GenoMEL, have now reported successes with denaturing
HPLC in identifying CDKN2A mutations (Orlow et al., 2001;
Edmunds et al., 2002; Lang et al., 2005; Marian et al., 2005;
Harland et al., 2008). Although direct sequencing and other
conformation-based screening strategies, such as denaturing
HPLC and high-resolution thermal melt analysis, unquestion-
ably drive discovery of, to our knowledge, previously
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unreported, mutations, they are limited in their multiplexing
capabilities. The maximal utility of this bead array depends
on the distribution and frequency of CDKN2A and CDK4
mutations. The GenoMEL consortium enriches for familial
cases that have a reasonable founder composition. In some
ways, this is an ideal collection to initially validate the assay,
as a limited panel of variants may in fact capture a significant
fraction of cases. However, broader application to the
general CMM population may not be appropriate, given the
current iteration of the assay. Along these lines, it is important
to note that this technology is not meant to replace discovery,
nor is it possible for the bead assay to account for all rare
variants within high-risk genes. Exciting advances in geno-
mics and ‘‘variomics’’ will continue in parallel with platforms
such as the bead assay. More robust assays will likely result in
greater capture of the melanoma variome. One potential
approach would be to perform a staged application. On first
pass, a bead ‘‘sweep’’ will identify the most prevalent risk
changes associated with melanoma. This can be followed by
a targeted resequencing of high-risk loci if founder changes
are not identified. Over time, total genomic resequencing
may replace platforms such as the bead assay, although the
voluminous influx of uncertain variants poses its own unique
challenges.
In conclusion, we have developed and validated the use of
a multiplex bead-based assay for the detection of 39 variants
associated with familial CMM in the GenoMEL consortium.
This multiplex bead-based assay is a fast, sensitive, high-
sample-throughput, cost-effective, and a reliable method
for the screening of CDKN2A and CDK4 mutations in a
large number of samples. This assay can be easily expanded
to include other variants, as they are reported, and can
be readily adapted to specific mutations in specific
populations.
MATERIALS AND METHODS
Patient samples
A total of 1,603 individual samples were genotyped. Of these
samples, 1,005 were accrued from March 1996 through to May
2004 for CDKN2A research-based genetic testing through the
Familial Melanoma Clinic at the Toronto-Sunnybrook Regional
Cancer Centre, and were from CMM-affected patients, their
unaffected relatives, and spouses. All patients gave informed written
consent to participate in this research study, allowing a portion of
their DNA sample to be used for CDKN2A testing and the remainder
to be banked for future studies. The remaining 598 samples were
from international melanoma pedigrees from the Melanoma
Genetics Consortium (GenoMEL, http://www.genomel.org). Ethical
committee approval was obtained from all institutions involved. The
study was conducted according to the Helsinki guidelines. The
GenoMEL samples included in the analysis are shown in Table 1.
Assay development and initial validation were performed in Toronto.
As part of the expanded Boston validation, the device was
transferred to the Massachusetts General Hospital and recalibrated.
All experiments in Boston were performed to the exact specification
of the protocols delineated in Toronto, except that primer sets were
resynthesized and beads were purchased separately from the
manufacturer.
DNA
For the subjects from Toronto, whose samples were used in develop-
ment of the assay, genomic DNA was isolated from whole blood with
Qiagen (Qiagen, Valencia, CA) QIAamp Blood Kits following the
manufacturer’s instructions. DNA samples were stored at 20 1C until
required. Before analysis, genomic samples were quantified spectro-
photometrically by measuring absorbance at 260nm, diluted to
5ngml1, and stored at 4 1C. For the GenoMEL validation cases, sample
derivation and DNA preparation were separately performed at each site;
genetic analysis based on the GenoMEL material has been previously
published (Goldstein et al., 2006, 2007).
DNA amplification
A total of 25ng of genomic DNA samples were subjected to multiplex
PCR amplifications, which contained 1ml of 10 PCR buffer
(Invitrogen, Carlsbad, CA), 0.3ml of 50mM Mg2þ , 1ml dNTPs, 0.6ml
PCR primer mix (0.1 pmol each; Integrated DNA Technologies,
Coralville, IA), 0.5ml DMSO, 0.5ml Platinum Taq DNA polymerase
(Invitrogen, Carlsbad, CA), and ddH2O, added to obtain a final volume
of 10ml. Samples were amplified for CDKN2A exons 1a, 2, and 3,
CDK4 exon 2 and p14ARF exon1b under the following cycling
conditions: 95 1C for 1minute, followed by 40 cycles of 95 1C for
30 seconds, 54 1C for 30 seconds, 72 1C for 30 seconds, and then an
extension time of 72 1C for 7minutes. Samples were kept at 4 1C until
ready for use. A negative PCR control was included in each multiplex
reaction. The primers and amplicon sizes for all PCR reactions are
shown in Supplementary Table S2 online. Multiplex PCR products
were analyzed by gel electrophoresis to confirm the presence of
discrete bands for each amplicon (data not shown). As the 1-8dup8
change is a perfect repeat and silent to the allele-specific methodology,
it was assayed by a PCR gel-based system and not by the bead analysis.
Amplicons were then subjected to exonuclease I/shrimp alkaline
phosphatase (Fermentas, Glen Burnie, MD) treatment for 1hour at 37 1C
to degrade any excess PCR oligonucleotides and inactivate any remain-
ing nucleotides, particularly deoxycytidine triphosphate, as biotin–
deoxycytidine triphosphate is incorporated during the primer extension
reaction. Samples were exonuclease I/shrimp alkaline phosphatase-
inactivated at 80 1C for 15minutes. The treated PCR products were then
diluted in the ratio 1:2 by the addition of 10ml of ddH2O.
Allele-specific primer extension reaction
The microsphere-based assay was performed as described by
Bortolin et al. (2004). Treated PCR products were used as the
template in an ASPE reaction, using SNP-specific oligonucleotide
pairs, one terminating with the wild-type base and the other with the
variant base (Supplementary Table S2 online).
The ASPE sequence-specific oligos are tagged at the 50 end with a
24-mer universal tag sequence (Luminex Molecular Diagnostics). The
ASPE reaction incorporates biotin-labeled deoxycytidine triphos-
phate in excess, which is used to quantify reaction products in the
Luminex xMAP flow cytometer.
ASPE reactions were carried out with 1.25ml exonuclease I/shrimp
alkaline phosphatase-treated PCR product, 0.5ml of 10 PCR
reaction buffer (Invitrogen), 0.125ml of 50mM Mg2þ , 0.1ml of 5mM
dNTP mix containing dATP, dGTP, dTTP (GE Healthcare, formerly
Amersham Biosciences, Piscataway, NJ), 0.25ml of 5mM biotin-
deoxycytidine triphosphate (Invitrogen), 0.125ml ASPE primer mix
(1.25pmolml1 each; IDT), 0.075ml of 5Uml1 of 10 PCR reaction
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buffer and ddH2O added to obtain a final volume of 5ml. The cycling
conditions were as follows: 96 1C for 2minutes, followed by 40 cycles
of 94 1C for 30 seconds, 54 1C for 30 seconds, and 74 1C for
30 seconds. Samples were then stored at 4 1C until ready for use.
A population of carboxylated microspheres (beads) tagged with
complementary (anti-tag) sequences were then hybridized directly to
the ASPE products by first denaturing the samples for 2minutes at
95 1C, and a reporter (streptavidin-conjugated phycoerythrin) was
added to detect incorporated biotin.
The hybridized products were then run through the Luminex
xMAP and classified on the basis of microsphere identification. The
presence of each allele was quantified by streptavidin-conjugated
phycoerythrin detection as described previously (Bortolin et al.,
2004). Figure 2 gives a schematic outline of the bead-based assay.
Statistical analysis
The raw median fluorescent intensity data were collected for each
bead population and base-lined by subtracting the value obtained for
a PCR control sample (no DNA) from each sample value (net median
fluorescent intensity). Genotypes were determined by calculating the
allelic ratios using the ratio of net wild-type or mutant median
fluorescent intensity per sum of wild-type and mutant median
fluorescent intensity for each SNP. This analysis could then
determine wild-type, mutant, and heterozygous SNP genotypes.
DNA sequencing
Bidirectional DNA sequencing was performed on all 1,005 samples
using an MJ Base station (MJ Research, Waltham, MA), as described
previously (Hogg et al., 2001), to compare sequences with the bead-
based assay genotyping results. The 628 samples supplied by
GenoMEL had previously been sequenced at source and at Leeds,
as part of studies for other GenoMEL initiatives.
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Figure 2. The bead-based assay. Regions of interest are initially amplified by multiplex PCR (for CDKN2A (cyclin-dependent kinase inhibitor 2A); the
primers are listed in Supplementary Table S1 online). Individual probes with the interrogative terminal codon are linked to a unique 24-mer Tag and subjected
to allele-specific primer extension (ASPE). The ASPE extension step uses biotinylated deoxycytidine triphosphates, thereby introducing a biotin-labeled
moiety into the extended fragment. The 24-mer Tag/biotinylated ASPE fragment is then specifically captured by a color-coded bead adorned with an
anti-Tag, which fully complements the 24-mer Tag sequence. Streptavidin-conjugated phycoerythrin (SA-PE) is then introduced to detect an intensity signal.
In summary, the bead color defines the address (that is, the individual single-nucleotide polymorphism (SNP)), while the PE fluorescence intensity defines
the amount of the specific SNP fragment. MUT, mutant; WT, wild type.
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